Posted by Michael Wonder on 09 May 2017
Cipher Pharmaceuticals receives Health Canada approval of Ozanex (ozenoxacin 1% cream)
8 May 2017 - Cipher Pharmaceuticals today announced the Health Canada approval of Ozanex (ozenoxacin 1% cream) a novel topical antibiotic indicated for the treatment of impetigo in patients aged 2 months and older .
“The approval of Ozanex offers a new and effective treatment option for young children suffering with one of the most common and contagious bacterial skin infections,” said Dr. Ian Landells, a Pediatric Dermatologist from St. John’s, Newfoundland. “It’s the first bacteriocidal topical antibiotic and has been shown to be effective against resistant bacteria such as MRSA.
